IL3 and the EV scaffold protein LAMP2B were fused to construct engineered LAMP2B-IL3 EVs, and siRNAs targeting CML cell oncogenes and the chemotherapeutic imatinib were loaded simultaneously to generate engineered EVs that targeted CML cells, inhibited cancer cell growth and reduced tumor size107. The gene discussed is IL3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.